Halozyme Therapeutics Inc. (HALO) and Baxter International Inc. (BAX) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has granted a Positive Opinion to Baxter for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies.
Halozyme Therapeutics gapped up sharply Friday and climbed above the session's narrow range in the final 2 hours of trade. Shares finished up by 1.63 at $6.90 on the highest volume in 3 months. The stock broke out to nearly a 2-month high and re-crossed both its 50 and 200-day moving averages.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.